| abstract |
A combined pharmaceutical preparation with lipase inhibitory properties which contains 0.2 to 100 mg of glucosidase blocker, acarbose, or O-4,6-dideoxy-4 - (1S, 4a), as active ingredients. 5.beta., 6.alpha.-4,5,6-trihydroxy-3- (hydroxymethyl) -2-cyclohexen-1-yl / amino.alpha.-D-glucopyranosyl- (1- 4) -O-α-D-glucopyranosyl- (1 >4) -D-glucose and 10-200 mg of lipase blocker, tetrahydrolipstatin, or 1,3-lactone (2S, 3S, 5S) -5- / (S) -2-formamido-4-methylvaleryloxy) -2-hexyl-3-hydroxyhexadecanoic acid based on unit dosage form. The use of acarbose for the production of combined pharmaceutical compositions with tetrahydrolipstatin with lipase inhibitory properties in the treatment of obesity. |